| Literature DB >> 27268204 |
Hong Luo1, Jennifer A Schmidt1, Yi-Shan Lee1, Eugene M Oltz1, Jacqueline E Payton1.
Abstract
Alterations to the epigenetic landscape of diffuse large B-cell lymphoma (DLBCL) play a fundamental role in deregulating genes involved in normal lymphocyte differentiation. To determine whether targeted epigenetic therapy could reverse these pathogenic chromatin changes and suppress the expression of a lymphoma oncogene, we focused on BCL6, a transcriptional repressor whose aberrant expression is tightly linked to DLBCL proliferation and survival. We fused zinc-finger (ZF) domains specific for regulatory regions in the BCL6 locus to a repressive epigenetic modifier, the Kruppel-associated box (KRAB) repressor domain. Distinct ZF-KRAB fusions repressed the local chromatin landscape, suppressed BCL6 expression, significantly impaired DLBCL growth, and caused widespread cell death in a BCL6-dependent manner. Importantly, expression of ectopic BCL6 protein rescued ZF-KRAB-induced cell death, demonstrating the modifiers' specificity. We show that sequence-specific epigenetic modifiers can alter oncogene expression and induce apoptosis in cancer cells, underscoring their potential for future development as targeted epigenetic protein therapies.Entities:
Keywords: Chemotherapeutic approaches; lymphoma and Hodgkin disease; transcription factor changes
Mesh:
Substances:
Year: 2016 PMID: 27268204 PMCID: PMC5206989 DOI: 10.1080/10428194.2016.1190973
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022